Intranasal Nanovaccine Confers Homo- and Hetero-Subtypic Influenza Protection.

Abstract

Cross-protective and non-invasively administered vaccines are attractive and highly desired for the control of influenza. Self-assembling nanotechnology provides an opportunity for the development of vaccines with superior performance. In this study, an intranasal nanovaccine is developed targeting the conserved ectodomain of influenza matrix protein 2(M2e). 3-sequential repeats of M2e (3M2e) is presented on the self-assembling recombinant human heavy chain ferritin (rHF) cage to form the 3M2e-rHF nanoparticle. Intranasal vaccination with 3M2e-rHF nanoparticles in the absence of an adjuvant induces robust immune responses, including high titers of sera M2e-specific IgG antibodies, T-cell immune responses, and mucosal secretory-IgA antibodies in mice. The 3M2e-rHF nanoparticles also confer complete protection against a lethal infection of homo-subtypic H1N1 and hetero-subtypic H9N2 virus. An analysis of the mechanism of protection underlying the intranasal immunization with the 3M2e-rHF nanoparticle indicates that M2e-specific mucosal secretory-IgA and T-cell immune responses may play critical roles in the prevention of infection. The results suggest that the 3M2e-rHF nanoparticle is a promising, needle-free, intranasally administered, cross-protective influenza vaccine. The use of self-assembling nanovaccines could be an ideal strategy for developing vaccines with characteristics such as high immunogenicity, cross-protection, and convenient administration, as well as being economical and suitable for large-scale production.

• Authors: Mi Qi, Xian-En Zhang, Xianxun Sun, Xiaowei Zhang, Yanfeng Yao, Siling Liu, Ze Chen, Wei Li, Zhiping Zhang, Jianjun Chen, Zongqiang Cui
• Journal: Small (Weinheim an der Bergstrasse, Germany) (Small) Vol. 14 Issue 13 Pg. e1703207 (03 2018) ISSN: 1613-6829 [Electronic] Germany
• PMID: 29430819 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Chemical References

• Influenza Vaccines
• M2 protein, Influenza A virus
• Viral Matrix Proteins
• Ferritins

Topics

• Administration, Intranasal
• Ferritins (genetics, metabolism)
• Humans
• Immunization (methods)
• Influenza A Virus, H1N1 Subtype (immunology, pathogenicity)
• Influenza A Virus, H9N2 Subtype (immunology, pathogenicity)
• Influenza Vaccines (immunology, therapeutic use)
• Influenza, Human (immunology, prevention & control, virology)
• Nanotechnology (methods)
• Vaccination (methods)
• Viral Matrix Proteins (immunology, metabolism)